graph NVAF
  • In the ARISTOTLE trial, weight had no significant effect on the efficacy or safety of apixaban
ARISTOTLE Weight Subgroup Analysis
  • In a retrospective subgroup analysis of the ARISTOPHANES study, apixaban was associated with a lower risk of stroke/SE and major bleeding versus warfarin in patients with obesity/morbid obesity
Deitelzweig S (J Clin Med. 2020)
Effectiveness and safety of oral anticoagulants among obese NVAF patients: insights from the ARISTOPHANES study
  • In a retrospective analysis of US Veterans Affairs and CMS Medicare data, apixaban was associated with a similar risk of stroke/SE, and a significantly lower risk of major bleeding, versus warfarin in patients with BMI ≥30 kg/m2 or body weight ≥100 kg
Deitelzweig (Am J Cardiol 2022)
Apixaban vs warfarin in obese patients with NVAF
enrolled in Medicare and VA